The SURMOUNT-1 trial demonstrated up to 22.5% body weight reduction with tirzepatide at the highest dose (15mg weekly), compared to semaglutide's 14.9% in STEP 1
doi: 10.1080/15548627.2023.2261758 239 EfferthT
For instance, in August 2024, Eli Lilly and Company, one of the leading producers of Trulicity, and Purdue University reinforced their well-established strategic research collaboration by launching a research alliance center named LPRC, which will focus on optimizing all stages of pharmaceutical research, from discovery to delivery
In the retatrutide trial data above, dysesthesia jumped from 8.8% at the 9 mg dose to 20.9% at the 12 mg dosea pattern that mirrors whats been seen with another GLP-1 medication at a higher dose
Zepbound users have reported serious gastrointestinal health issues, including gastroparesis and gastroenteritis
doi: 10.3109/00498257809069589 107 AsaiAMiyazawaT